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Abstract
Background: The ILEP Nerve Function Impairment in Reaction (INFIR) is a cohort study designed to identify predictors of
reactions and nerve function impairment (NFI) in leprosy.
Aim of the Study: Antibodies to mycobacteria, nerve components and serum cytokine were measured as potential markers
for their possible association with reactions and NFI.
Patients and Methods: 303 newly diagnosed leprosy patients from two centres in North India were enrolled. Antibodies to
PGL-1, LAM (IgG1 and IgG3), ceramide, S100 and TNFa levels were measured using ELISA techniques.
Results: S-100, PGL IgG and IgM antibody levels were lowest in patients with BT leprosy and highest in patients with
lepromatous leprosy. LAM IgG1 and LAM IgG3 antibody levels were highest in patients with BL leprosy. Ceramide antibody
levels were not correlated with type of leprosy. Levels of all the antibodies tested and TNF a were lowest in patients with
only skin reaction. PGL IgM antibody levels were elevated in patients with skin reactions and NFI. Old sensory NFI is
associated with significant elevation of PGL IgG, LAM IgG and S100 antibody levels.
Conclusion: These results reveal that the antibody response to mycobacterial antigens, nerve antigens and cytokines are in
a dynamic flux and could collectively contribute to NFI in leprosy. The association of multiple markers with old NFI may
indicate the contribution of different pathological processes.
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Introduction
Leprosy is a chronic granulomatous disease affecting skin and
nerve. There is a range of clinical and immunological responses
to infection with Mycobacterium leprae and the disease manifests as a
spectrum. At the tuberculoid end of the spectrum there is a well
developed immune response and mycobacteria are eliminated
with a granulomatous response in skin and nerve which may
produce severe destruction of peripheral nerves[1]. At the
lepromatous end of the spectrum there is little cell mediated
immunity and mycobacteria proliferate in skin and nerves and
macrophages infiltrate skin and nerve but with no organised
response. Most patients have one of the borderline types of
disease in which some mycobacteria are present with a
lymphocytic and macrophage infiltration of skin and nerve.
Mycobacterial antigens are presented to the immune system and
initiate a T cell response with macrophage activation and the
production of pro-inflammatory cytokines. This inflammation in
peripheral nerves produces local destruction of nerve structures,
with subsequent loss of nerve function, which puts patients at risk
of developing impairments. The pathogenesis of leprosy reactions
and nerve damage involves either cell-mediated immunity at sites
of localisation of mycobacteria (reversal reaction) [2] or immune-
complex syndrome due to precipitation of antigen and antibody
complexes in tissue spaces and in blood and lymphatic vessels
(ENL) [3]. Identifying patients who are at risk of developing
nerve damage is therefore a key challenge in leprosy. Various
cohort studies have identified clinical risk factors for the
development of nerve damage. Studies in Bangladesh [4],
Ethiopia [5] and Thailand [6] have shown that multibacillary
leprosy (MB), increasing age and the presence of nerve damage at
the time of diagnosis are risk factors for the development of
further nerve damage. However, few studies have looked at
laboratory parameters as risk factors.
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Phenolic glycolipid (PGL-1) is a M.leprae specific antigen and
90% of lepromatous, but only 50% of tuberculoid patients have
antibodies to PGL-1 in proportion to their mycobacterial load [7].
A study in Nepal showed that seropositivity for PGL-1 IgG
antibodies when anti-leprosy treatment is started was a significant
risk factor for the development of Type 1 reactions (T1R) [8].
However this finding has not been confirmed in other small studies
in Nepal [9] and Brazil [10]. We hypothesised that raised PGL-1
levels would be a risk factor for developing reactions and nerve
damage as well as being correlated with bacterial load.
Lipoarabinomannan (LAM) is a polysaccharide antigen present
in M. leprae and is involved in initiating a specific humoral response
in leprosy patients [11]. As a B cell immunogen it might have a
role in part of the pathogenesis of nerve damage. LAM antigen
persists in the body after the completion of antibacterial treatment
and has been shown to be associated with leprosy reactions in skin
and nerve biopsies [2]. One study has shown an association
between raised LAM antibody levels and the occurrence of T1R
[12]. LAM was considered as a potential candidate antigen in the
pathogenesis of leprosy reactions, especially the late reversal
reactions because it may persist in skin and nerve lesions [2]. We
hypothesised that LAM antibody levels would be increased in
patients with a high bacterial load and in patients with reactions.
Humoral responses against nerve antigens are pathogenic in
some peripheral and sensory peripheral neuropathies [13] and
may also have a role in leprosy nerve damage. Ceramide and other
sphingolipids are recognised as lipid mediators of the immune
response and high concentrations of auto-antibodies to neural
proteins and lipid antigens have been demonstrated in leprosy
patients [14],[15], [16]. It has been reported that leprosy patients
across the Ridley-Jopling spectrum show antibodies against
ceramide in their sera [17,18].
S100 is a specific nerve tissue protein. Narayan et al looked for
S100 antigen levels in serum and found that 87.5% of the patients
had elevated S100 antigen levels. The studies of Vemuri et al [18],
Narayan et al [17] and Eustis-Turf et al [14], although important
in suggesting a pathogenic role for antibodies in the development
of nerve damage, all lack information on the neurological status of
the patients thus making it impossible to confirm the association
with clinical nerve damage.
Tumour necrosis factor a (TNFa) is a pro-inflammatory
cytokine that is particularly implicated in the pathogenesis of
mycobacterial infections. Previous studies have shown that TNFa
is produced in skin and nerve during leprosy T1R [19]. Raised
serum TNFa levels have been reported in Erythema Nodosum
Leprosum (ENL) reactions and one could hypothesise that TNFa
might leak from sites of inflammation into the circulation and so
be a marker of acute leprosy related inflammation. Serum TNFa
levels are found to be high in LL and low/undetectable in BT-TT
patients [20].
The INFIR cohort comprised 303 newly diagnosed patients
with MB in North India who were recruited to a study looking for
risk factors for nerve damage and reactions in leprosy patients
[21]. After recruitment they were assessed monthly for a year and
then every two months until 24 months after diagnosis. This study
design enabled us to correlate serological and clinical findings. At
recruitment, patients were asked about the presence of new nerve
damage which was defined as nerve damage occurring within the
last six months. This then allowed us to look at pathological
associations of recent or long-term nerve damage. We were
therefore able to test the following hypotheses:
1. PGL-1 antibody levels would correlate with bacterial load and
be a risk factor for the presence of reaction and nerve damage.
2. LAM antibodies would be elevated in patients with reactions
and nerve damage.
3. TNFa levels would be high in patients with T1R and nerve
damage since these are acute inflammatory events with local
production of TNFa.
4. Anti-ceramide and S100 levels would be increased in patients
with new nerve damage and neuritis but not patients with only
skin reactions.
Here we report the findings from the baseline when patients
were recruited into the study.
Materials and Methods
Ethical considerations
No financial incentives were given to participants. However,
travel expenses were refunded on occasion and, where relevant,
lost earnings of daily labourers compensated. The study adhered
to the International Ethical Guidelines for Biomedical Research
Involving Human Subjects (CIOMS/WHO, 1993). Permission for
the study was obtained from the Indian Council of Medical
Research and ethical approval was given by the Research Ethics
Committee of the Central JALMA Institute for Leprosy in Agra.
This included permission for the skin and nerve biopsies. Written
consent was obtained from individual subjects before inclusion in
the study, using a standard consent form.
Design
This was a cohort study of 303 newly registered MB patients.
The patients were followed up monthly for one year and every
second month during the second year.
Location
Recruitment of subjects took place in The Leprosy Mission
(TLM) hospitals in Naini and Faizabad, specialist leprosy referral
centres in Uttar Pradesh, North India. The immunological and
histopathological investigations were carried out at the LEPRA
Society Blue Peter Research Centre in Hyderabad, Andhra
Pradesh and at the TLM Stanley Brown Laboratories formerly
located in Miraj, Maharashtra. Normal control sera were obtained
from the Department of Transfusion Medicine, Nizam’s Institute
Author Summary
Leprosy is one of the oldest known diseases. In spite of the
established fact that it is least infectious and a completely
curable disease, the social stigma associated with it still
lingers in many countries and remains a major obstacle to
self reporting and early treatment. The nerve damage that
occurs in leprosy is the most serious aspect of this disease
as nerve damage leads to progressive impairment and
disability. It is important to identify markers of nerve
damage so that preventive measures can be taken. This
prospective cohort study was designed to look at the
potential association of some serological markers with
reactions and nerve function impairment. Three hundred
and three newly diagnosed patients from north India were
recruited for this study. The study attempts to reflect a
model of nerve damage initiated by mycobacterial
antigens and maintained by ongoing inflammation
through cytokines such as Tumour Necrosis Factor alpha
and perhaps extended by antibodies against nerve
components.
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of Medical Sciences (NIMS), Hyderabad and Miraj Medical
Centre (Wanless Hospital), Miraj.
Study population
The study population comprised newly registered MB patients
requiring a full course of Multi Drug Therapy. A detailed
description of the study design has already been published [22].
Definitions of reactions and nerve function impairment
Nerve function assessment: Nerve function impairment (NFI)
was present when a patient had either or both of motor or sensory
loss which were assessed by voluntary muscle testing and testing
with Semmes –Weinstein monofilaments as described previously
[21]. NFI was categorised as old when signs and symptoms had
been present for more than six months and new when signs and
symptoms had been present for six months or less.
Type 1 or Reversal Reaction (T1R): T1R was diagnosed when a
patient had erythema and oedema of skin lesions. This may have
been accompanied by neuritis and oedema of the hands, feet and
face.
A patient could have a skin reaction only, or a nerve reaction, or
a skin and nerve reaction.
Erythema Nodosum Leprosum (ENL): ENL was diagnosed
when a patient had crops of tender subcutaneous skin lesions.
There may have been accompanying neuritis, iritis, arthritis,
orchitis, dactylitis, lymphadenopathy, oedema and fever.
Database
All the data obtained in the study, including the clinical,
neurophysiological, serological and histopathological data, were
entered on computer locally and subsequently merged into a single
Microsoft Access database. Further details of the study plans,
methods, definitions, documentation and the status of the cohort
at baseline have been published [21].
Materials
S100 protein, Anti-human IgG Peroxidase conjugate, Mono-
clonal Anti-human IgG1, Anti-human IgG3, Anti-mouse IgG
(gamma chain specific) Ceramide, Anti-human IgM (peroxidase
conjugated), Avidin peroxidase, Orthophenyl Diamine (OPD)
tablet, Tween 20, Carbonate-bicarbonate buffer capsules, Phos-
phate citrate buffer tablets and bovine serum albumin (BSA) were
obtained from Sigma Aldrich, USA. ManLAM and disaccharide
conjugate of PGL was kindly provided by Prof. Patrick Brennan,
Colorado State University. Monoclonal antibodies to TNFa
(capture antibody), secondary antibody (detection antibody) and
recombinant TNFa standard were obtained from R & D Systems,
London. Chemicals for phosphate buffer were obtained from
Merck, the Immulon-2B ELISA plates from Thermo Labsystems,
Finland and the plate sealers from Linbro, ICN, USA.
Laboratory methods
Serum samples from the patients at the time of recruitment
(baseline samples) were tested for various parameters. The
different serological parameters tested using ELISA technique
were: antibodies to the M.leprae – PGL and LAM; antibodies
against nerve components S100 and ceramide and the proin-
flammatory cytokine TNFa.
ELISA for antibodies against S100,PGL-I, LAM and ceramide:
Antigens against which the antibodies were to be tested were
dissolved in suitable solvent like deionised water (S-100 and PGL-
I), or 70% methanol in PBS (ManLAM) or PBS (ceramide).
ELISAs were carried out as follows: briefly 96well microtitre plates
(Dynatech) were coated with the antigen at a concentration of 0.1
mg/well in 0.05 M carbonate-bicarbonate buffer pH 9.6 by
incubating overnight at 37 uC (for S-100, PGL-I and LAM). For
anticeramide the antigen in PBS was sonicated prior to coating to
obtain uniform suspension. The plates were washed 4 times (46) in
phosphate buffered saline with Tween 20 (PBS-T) and then
blocked with 2%BSA in PBS for 1K hr at 37 uC in a humidified
chamber. After washing 46with PBS-T, test sera (1:100 dilution)
were added (100 ml/well) in triplicate. Standard pooled sera (sera
showing high antibody titre against the antigen to be tested) were
used for the S-100, PGL-I and LAM ELISAs. Twofold dilutions
were used ( 1:25 to 1:800 for S-100 and LAM ELISAs, 1:100 to
1:3200 for PGL-I IgG and 1:200 to 1:6400 for PGL-I IgM).The
dilutions were assigned arbitrary units. The lowest dilution of the
sera was assigned 200 AU whereas subsequent dilutions were
assigned AU values accordingly e.g. 1:100 dilution for PGL-I IgG
was assigned 200 AU whereas 1:200 dilution was assigned 100 AU
and so on. The O.D. values of different dilutions of the standard
pooled sera were then plotted against the assigned AU values to
get a standard graph. Thus using the same standard pooled sera
we could prepare a standard graph to test the antibody levels for
all the samples tested so that we could compare the results. Plates
were incubated at 37 uC for 1K hr in a humidified chamber and
then washed 46with PBS-T. For S-100, PGL-I IgG and ceramide
ELISAs 100 ml of anti-human IgG- horse radish peroxidase
(HRPO) was added to the wells whereas for PGL-I IgM ELISA
anti-human IgM-HRPO was used. Plates were incubated at 37 uC
for 1K hr. For LAM IgG1 and IgG3 antibody ELISA the
procedure used was as described earlier by Beuria et al [12] i.e.
after the steps of addition of test / standard sera and plate washing,
and prior to addition of enzyme conjugated antibody, 100 ml of
mouse anti-human IgG1or mouse anti-human IgG3 monoclonal
antibody (1:3000 and 1:2000 diluted respectively) was added to the
plate and incubated at 37C for 1K hr in a humidified chamber
and then washed 46 with PBS-T. Then 100 ml goat anti-mouse
IgG-HRPO conjugate was added at dilution of 1:3000 for LAM-
IgG1 ELISA or 1:2000 for LAM-IgG3 ELISA. Plate was
incubated at 37 uC for 1K hr in a humidified chamber and then
washed 46with PBS-T.
After washing, OPD substrate (in phosphate citrate buffer with
perborate pH 5.0) at a final concentration of either 0.4 mg/ml (S-
100, PGL-I) or 1 mg/ml (LAM-IgG1 and IgG3) was added. For
anti-ceramide antibody ELISA OPD substrate (1 mg/ml) in
phosphate citrate buffer containing 0.06% H2O2 was added.
The reaction was stopped with 3N HCl (for S-100, LAM and
PGL-I) or 3N H2SO4 (for anticeramide) after incubating at 37 uC
for 15 minutes. The optical density (OD) was measured using a
dual filter at the wavelength of 490/630 nm (Dynatech).
Estimation of serum TNFa: Sandwich ELISA development kit
from R&D was used to detect serum TNFa. Briefly, the
monoclonal antibodies to TNFa were coated onto the ELISA
plate (Immulon-2B) at a concentration of 300 ng/well and
incubated overnight at room temperature (26 uC). The next day,
the plate was blocked in 2% BSA and incubated with 200 ml of test
sera for 2 hr which are then detected by biotinylated secondary
antibodies. The plate was then treated with Avidin peroxidase
diluted according to manufacturers’ instructions and developed by
adding substrate OPD at a concentration of 1 mg/ml in
Phosphate Citrate buffer pH 5.0 containing 0.06% H202 for 15
minutes in dark. The reaction was terminated with 50 ml of 3N
H2SO4 and the colour was read at 490 nm. Every step until
substrate addition was followed by five washing cycles pro-
grammed in Biorad plate washer with PBS pH 7.4 containing
0.1% BSA and 0.05% Tween 20. For TNFa, OD values were
Serological Markers in Leprosy Reactions
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entered into the database. For the full data set TNF concentrations
(pg/ml) were then computed by applying the manufacturer’s
standard transformation based on a straight line relationship
between the logarithm of the inverse OD and the logarithm of the
inverse concentration.
Analysis of results
Statistical analysis was performed using Stata. The significance
of association between outcome and predictor variables was tested
using chi-squared tests or Fisher’s exact test as appropriate.
Differences between means or medians were tested with Student’s
t test or the Kruskal-Wallis test.
Results
One hundred and fifteen patients had a reaction or new NFI at
baseline. Table 1 gives the details of the nerve impairment found
at baseline. One hundred and forty three patients (47.2%) had NFI
at baseline. 67 (21.1%) had new impairment detected by
monofilament or VMT. Old sensory nerve damage was the
commonest impairment, being detected in 104 (34.3%) patients
and new sensory damage in 50 (16.5%) patients. Motor damage
was detected less often, with 26 (8.6%) patients having old and 33
(10.9%) new motor nerve damage. Fifty four (17.8%) had a T1R.
One hundred and ninety three patients of the whole cohort (303)
were slit skin smear negative for leprosy bacilli at diagnosis. Of this
subgroup 60 had a reaction or NFI at baseline with 22 having a
T1R, 39 new NFI and 15 other neuritis. Sera taken at time of
diagnosis were available for all patients recruited to the study. This
was tested for all seven serological markers. Since the focus of this
study was to identify associations with pathological processes and
nerve damage the findings are presented first by Ridley-Jopling
classification and then by type of reaction and nerve damage.
Antibody and Cytokine levels in the different Ridley-
Jopling classification groups
PGL IgG and IgM antibody levels increased significantly
across the Ridley-Jopling spectrum groups with lowest levels in
the BT patients and the highest in LL patients (Table 2)
(p,0.001). Levels of LAM IgG1 and IgG3 were also significantly
higher in BL than BT patients (p,0.01). S100 levels increased
across the Ridley-Jopling spectrum with LL patients having
higher levels than BT patients (p,0.01). TNFa levels were highly
variable with a tendency to be lower in LL patients than patients
with BT and BL; however, because of the wide variation, none of
the apparent differences reached statistical significance. Antibody
and cytokine levels in control sera collected from normal subjects
were also tested. Levels of all the antibodies and TNFa were
significantly low in controls compared to patients. As shown in
Table 2, patients were also classified by bacterial load. PGL IgG
and IgM levels were significantly higher (p,0.001) in patients
with higher bacterial loads, as were LAM levels in patients with
higher bacterial loads. PGL IgG and IgM levels were also
significantly higher in smear negative BL compared with smear
negative BT patients (p,0.001) (data not shown). S100 levels
were also significantly higher in patients with higher bacterial
loads.
Antibody and Cytokine Levels in reactions
In Table 3 the antibody and cytokine marker levels for patients
with and without reactions and NFI are compared. PGL-1 IgG
and IgM levels tended to be raised in the presence of nerve
damage or reactions but the differences did not reach statistical
significance. The lowest mean levels of all seven markers were
found when T1R occurred only in the skin with no NFI. A
significant decrease in the levels of anti-ceramide antibody levels
Table 1. Reactions and nerve damage status of 303 subjects recruited into study.
Total number recruited 303
In reaction (all forms) 115 (38.0%)
Not in reaction 188 (62.0%)
Reaction status (overlapping groups)
Type 1 reaction 54 (17.8%)
Type 2 reaction 5 (1.7%)
New NFI by MF or VMT 67 (22.1%)
Other neuritis 23 (7.6%)
Different types of nerve function impairments (overlapping groups)
No sensory NFI 149 (49.2%)
New Sensory NFI 50 (16.5%)
Old sensory NFI 104 (34.3%)
No motor NFI 244 (80.5%)
New motor NFI 33(10.9%)
Old motor NFI 26 (8.6%)
Old and new NFI by monofilament (overlapping groups)
Old sensory loss with no new sensory loss 104 (34.3%)
New sensory loss with or without old sensory loss 50 (16.5%)
Old motor loss with no new motor loss 26 (8.6%)
New motor loss with or without old motor loss 33 (10.9%)
Only old loss, sensory or motor 102 (33.7%)
doi:10.1371/journal.pntd.0000977.t001
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also occurred when there were T1R with and without new NFI
(p,0.01). This might be indicative of a marker that is altered when
only skin pathology is occurring. TNF levels were highest in
patients with NFI but these differences were not significant. We
found no statistically significant association between Ridley-
Jopling classification and reaction type.
Antibody and Cytokine Levels and Nerve Function
Impairment
In Table 4 patients were grouped according to the type of
NFI that they had. Patients with old sensory NFI had
significantly increased levels of PGL IgG, LAM IgG1 and
S100 antibody (p,0.05 or less). There were far more patients
with sensory NFI (154) compared to motor NFI (59). It was
observed that 136 patients did not have any NFI at the time of
recuitment. There were 149 patients with no sensory NFI. But
out of these 149 patients, 13 patients were with motor NFI (old/
new). Similarly there were 244 patients with no motor NFI, out
of which 108 patients had sensory NFI (old/new). Patients with
no old or new sensory loss. None of the markers were
significantly elevated in patients with old and new motor NFI.
TNFa levels were non-significantly elevated in patients in both
sensory NFI and new motor NFI. An analysis of antibody levels
in the 192 smear negative group patients showed that patients
with new sensory nerve damage had significantly higher PGL-1
IgG and LAM IgG1 levels (p,0.01 and p = 0.01, respectively)
(data not shown). PGL-1 IgM and S100 levels were higher, but
the significance level was borderline (p = 0.08 and p = 0.056,
respectively). There were no differences between anti-ceramide
and TNFa levels in the groups with or without sensory or motor
nerve impairment.
Discussion
The INFIR cohort study was a prospective study with carefully
designed case definitions and outcomes, which were supported by
clinical measurements. The large database has enabled us to
analyse the data and correlate the serological findings to specific
patient groups. The aim was to detect association between
laboratory findings and clinical parameters in a large patient
group.
Trends of antibody response in relation to leprosy type and
bacterial index were as expected and reported earlier by Schwerer
et al [23]. One of the specific objectives was to identify new
markers for nerve damage. We found an association between
bacterial load, mycobacterial antigens, auto-immunity and
inflammation and the development of nerve damage. Our
strongest finding was confirming the association between PGL-1
antibody levels and the occurence of reactions and nerve damage.
This association is also seen in the association between Ridley-
Jopling type leprosy and the presence of reactions or new nerve
damage. This association was also present in smear negative
patients. This finding has been reported before in a study done in
Nepal looking at risk factors for the development of leprosy
reactions [8]. It has also been recently reported from a large
cohort study in Bangladesh looking for predictive factors for nerve
damage [24]. Here the strength of the predictive model was
increased from 72% to 80% in the presence of PGL-1 antibodies.
One of the limitations for comparison of results with that of
normal control sera in this study was that though we used sera
from the subjects without neurological disease from the leprosy
endemic area, it was not from the same area as that from where
the patients were recruited.
Table 2. Antibody and cytokine mean, standard deviation and median within Ridley Jopling groups and BI groups.
Test
Medians and
standard devetions
Normal
Controls
Leprosy
(n =303)
BT Group
(n =185)
BL Group
(n=89)
LL Group
(n=29)
BI Negative
(n =193)
BI 0.1–3.0
(n =68)
BI 3.1–6
(n=42)
PGL – IgG
(AU)
18.6618.2
(n = 160)
97.76125.0
67.0
54.3638.5
51.0
147.36159.8
106.0
222.16205.4
162.0
55.5643.8
49.0
113.3672.6
104.5
266.56243.9
157.5
PGL – IgM
(AU)
17.9614.3
(n = 160)
153.56323.9
71.0
61.4644.2
51.0
260.96471.5
106.0
411.16508.6
177.0
73.7697.1
54.0
133.66112.8
102.5
552.06717.5
171.0
LAM – IgG1
(AU)
0.561.9
(n = 160)
11.0621.2
2.0
8.9620.6
1.0
15.6623.4
7.0
10.1615.6
3.0
9.6620.7
1.0
15.8625.4
4.0
10.0614.7
4.5
LAM – IgG3
(AU)
1.462.5
(n = 160)
9.6616.8
5.0
7.4610.5
4.0
14.3625.7
7.0
9.5612.7
5.0
7.9611.4
4.0
14.3628.3
6.0
10.0611.3
6.0
S-100 Antibody
(AU)
28.7628.5
(n = 160)
61.9645.7
50.0
55.0638.7
45.0
71.4656.0
55.0
76.8645.4
74.0
55.7639.7
47.0
62.3635.2
59.0
90.0670.7
64.5
Anticeramide
Antibody
(O.D)
0.260.2
(n = 286)
0.760.5
0.6
0.760.4
0.6
0.760.5
0.6
0.960.7
0.7
0.760.4
0.6
0.760.5
0.5
0.960.7
0.7
TNF alpha pg/ml
(Concentration)
14.07645.08
(n = 243)
49.06135.8
2.3
52.66138.5
2.2
55.46149.8
2.9
6.069.4
3.1
55.46141.6
2.2
38.06106.6
2.5
37.06151.1
3.7
Notes:
Kruskal-Wallis non-parametric testing used for all significance testing. Baseline serum was available from all 303 cases in the study. Anticeramide was not assessed for 7
individuals. Differences in markers across three Ridley-Jopling groupings reached statistical significance in five markers.
For PGL1_IgG, BT versus BL (p,0.001), BTvLL (p,0.001), BLvLL (p,0.05). Three pairwise comparisons between smear groups all had p,0.001.
For PGL1_IgM, BT versus BL (p,0.001), BTvLL (p,0.001), BLvLL (NS). Three pairwise comparisons between smear groups all had p,0.001.
For LAM_IgG1, BT versus BL (p,0.001), BTvLL (NS), BLvLL (NS). Only Negative smear 1-3 smear reached statistical significance (p,0.01).
For LAM_IgG3, BT versus BL (p,0.001), BTvLL (NS), BLvLL (NS). negative smear versus 1-3 smear (p,0.001) and negative smear versus 3+ smear (p,0.05) reached
statistical significance.
For S100, BT versus BL (p,0.01), BTvLL (p,0.05), BLvLL (NS). Only negative smear versus 1-3 smear reached statistical significance (p,0.01).
For Anticeramide, only negative smear versus 3+ smear approached significance (p = 0.054).
doi:10.1371/journal.pntd.0000977.t002
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We had predicted that S100 and anti-ceramide antibodies
would be raised in acute nerve damage but found no evidence of
this. However, both antibodies were elevated in patients with old
sensory nerve damage. One explanation for this might be that
auto-antibodies are not implicated in the initiation of new nerve
damage, but once the nerve is damaged, then various nerve
antigens may be presented to the immune system, initiating an
auto-immune response. This may be one mechanism whereby
nerve damage is perpetuated. The ongoing nerve damage seen in
treated leprosy patients is an important clinical problem and this
association should be investigated further.
Antibodies against LAM were associated with leprosy type, but
not with reactions, except with the presence of old sensory NFI.
This suggests that LAM might have some role in the initiation of
nerve damage, but has little immunogenic role in the ongoing
process of nerve damage.
We also found a non-significant association between elevated
TNFa levels and new sensory and motor nerve damage. TNFa is
a cytokine crucial for granuloma formation and also in the
mediation of local tissue damage [25]. TNFa has been reported
to cause demyelination and death of oligodendrocytes in a dose
dependent manner in in-vitro studies [26]. A previous study has
demonstrated TNFa in reactional skin and nerve lesions and this
finding suggests that TNFa might leak from the nerve lesions
into the circulation [19]. A variable elevation of TNFa has been
found in ENL reactions [27,28] and given the close association
of TNFa with the pathology of T1R, we predicted that TNFa
levels would be elevated. However, the TNF assay detected a
wide range of TNFa values. These levels were not easily
explicable either in terms of the patients’ leprosy pathology or
other possible ongoing pathologies. Other reports also document
a range of TNF values and a lack of correlation with clinical
outcome in leprosy patients [29]. Maybe this is an inherent
problem of studying this cytokine in the circulation. We had
expected that, with a large number of patients, a tighter range of
values might be found. Skin and nerve are very different
compartments and it may be that in the context of the leprosy
damaged peripheral nerve TNFa leaks more easily into the
circulation than from inflamed skin lesions. Andersson et al has
shown that in T1R there is marked compartmentalisation of
pathology and that cytokines may not leave the skin site for the
circulation [29]. This finding will be further tested when the
longitudinal data on patients in this cohort who developed
reactions and nerve damage during follow up are analysed.
One explanation for the absence of an association between
serological markers and motor damage might be that sensory
nerve damage is readily detected with monofilaments, whereas
motor nerve loss has to be quite advanced before it is detected
by the voluntary muscle testing as was used here. In further
analyses of the data, more sensitive tests of nerve function such
as nerve conduction studies will be analysed and associations
between mild motor damage with antibody levels can then be
tested [30].
This study did not find a new serological marker for the
detection of leprosy reactions. However, a pattern of associations
between markers and nerve damage has been shown. These would
be consistent with a model of nerve damage which is initiated by
mycobacterial antigens such as PGL-1, is maintained by ongoing
inflammation through cytokines such as TNFa and then perhaps
extended by auto-antibody-mediated nerve damage. It is impor-
tant that further work should be done to identify markers
associated with these different aspects of nerve damage. A small
Table 3. Antibody and cytokine mean, standard deviation and median in patients with and without reactions.
Test Value
Mean and standard deviation Patient Groups
No reaction
(n=188)
Reaction
(n =115)
Only skin reaction
(n=28)
Skin reaction + NFI
(n=17)
Only NFI
(n =48)
PGL – IgG
(AU)
93.96120.3
63.5
103.96132.6
74.0
82.6699.1
54.0
87.6669.0
75.0
102.16137.0
73.5
PGL – IgM
(AU)
138.36265.5
66.5
178.36401.6
73.0
98.96134.5
63.0
207.46439.4
78.0
175.46474.2
71.5
LAM – IgG1
(AU)
11.4621.6
1.0
10.4620.7
2.0
9.0628.1
0.0
11.2615.
3.0
11.4618.0
3.5
LAM – IgG3
(AU)
9.5619.3
4.0
9.8611.8
5.0
8.167.9
4.0
11.2616.4
5.0
9.269.9
6.0
S-100 Antibody
(AU)
64.8648.0
53.0
57.3641.6
47.0
52.1642.9
39.0
53.8628.4
45.0
56.8639.6
47.0
Anticeramide Antibody
(O.D)
0.760.5
0.6
0.760.5
0.6
0.560.3
0.4
0.560.3
0.4
0.860.5
0.7
TNF alpha
(Concentration)
43.96112.9
2.1
57.26166.7
2.9
13.9631.9
2.1
61.96157.3
3.2
103.46232.1
2.4
Notes:
AU – Arbitrary Units, O.D – Optical Density, Kruskal-Wallis non-parametric testing used for all significance testing. Baseline serum was available from all 303 cases in the
study. Anticeramide was not assessed for 7 individuals. For LAM_IgG1, Skin Only versus NFI Only p,0.05, Skin Only versus Skin+NFI p,0.05, For Anticeramide, Skin Only
versus NFI Only p,0.01, NFI Only versus Skin+NFI p,0.05.
We used a regression-based approach to assess the more complex relationships between reaction type, Ridley-Jopling type and each cytokine or marker as outcome.
Differences achieving statistical significance were as follows:
PGL1_IgG: Differences between BL and BT groups approached statistical significance (p = 0.054). After adjusting for Ridley-Jopling type differences between reaction
types failed to reach statistical significance. We found a statistically significant interaction effect (p,0.001), seen in high levels of PGL1_IgM among BL cases with
reactions including NFI. S110: We found a statistically significant interaction effect, with LL cases having the lowest levels of S100 and individuals with NFI-only reactions
having the highest (p,0.05). TNFalpha: After adjusting for Ridley-Jopling type we found a difference between reactions with both skin and NFI compared with skin-only
reactions (p,0.001). BL cases had the highest levels of TNFalpha, particularly among cases with NFI-only reactions (p,0.05).
doi:10.1371/journal.pntd.0000977.t003
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study from Brazil showed that plasma levels of CXCL10
(Inflammatory protein 10 ) and IL6 were raised in 10 patients
with T1R [31]. It would be useful to test these marker and other
future markers in this well-characterised cohort to evaluate their
role in the diagnosis of leprosy reactions.
There are several implications arising from this work. The
association of nerve damage with a marker for bacterial load
emphasises the need to detect and treat patients as early as
possible. However, we also need a marker for nerve damage in
patients who are bacteriologically negative, since this study shows
that there is also substantial nerve damage occurring in patients
who are slit skin smear negative.
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